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Abstract
We present the first computational kinetic model of polyamine metabolism in bloodstream-form Trypanosoma brucei, the
causative agent of human African trypanosomiasis. We systematically extracted the polyamine pathway from the complete
metabolic network while still maintaining the predictive capability of the pathway. The kinetic model is constructed on the
basis of information gleaned from the experimental biology literature and defined as a set of ordinary differential equations.
We applied Michaelis-Menten kinetics featuring regulatory factors to describe enzymatic activities that are well defined.
Uncharacterised enzyme kinetics were approximated and justified with available physiological properties of the system.
Optimisation-based dynamic simulations were performed to train the model with experimental data and inconsistent
predictions prompted an iterative procedure of model refinement. Good agreement between simulation results and
measured data reported in various experimental conditions shows that the model has good applicability in spite of there
being gaps in the required data. With this kinetic model, the relative importance of the individual pathway enzymes was
assessed. We observed that, at low-to-moderate levels of inhibition, enzymes catalysing reactions of de novo AdoMet (MAT)
and ornithine production (OrnPt) have more efficient inhibitory effect on total trypanothione content in comparison to
other enzymes in the pathway. In our model, prozyme and TSHSyn (the production catalyst of total trypanothione) were
also found to exhibit potent control on total trypanothione content but only when they were strongly inhibited. Different
chemotherapeutic strategies against T. brucei were investigated using this model and interruption of polyamine synthesis
via joint inhibition of MAT or OrnPt together with other polyamine enzymes was identified as an optimal therapeutic
strategy.
Citation: Gu X, Reid D, Higham DJ, Gilbert D (2013) Mathematical Modelling of Polyamine Metabolism in Bloodstream-Form Trypanosoma brucei: An Application
to Drug Target Identification. PLoS ONE 8(1): e53734. doi:10.1371/journal.pone.0053734
Editor: Andrew R. Dalby, University of Westminster, United Kingdom
Received September 4, 2012; Accepted December 4, 2012; Published January 23, 2013
Copyright:  2013 Gu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work was carried out under a PhD programme partly funded by Prof. Ray Welland, School of Computing Science, University of Glasgow. Further
work was unfunded. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have the following interests. David Reid is employed by Gold Standard Simulations Ltd. This does not alter the authors’
adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
* E-mail: Xu.Gu@igmm.ed.ac.uk
Introduction
The development of drugs to combat human African trypano-
somiasis (HAT) has become a major public concern due to
toxicity, inefficacy and availability problems with current drug
treatments [1,2]. Identification of potential drug targets within the
T. brucei parasite is an invaluable tool for designing chemother-
apeutic agents against the disease. A challenge in drug design
arises from the similarity of metabolic pathways in parasitic
protozoa and their mammalian hosts, resulting in toxicity to the
host as well as the parasite. Anti-parasitic drugs that are efficient,
non-toxic and affordable are urgently required.
Polyamines are ubiquitous cellular components that are
essential for cell growth and division. Polyamine metabolism in
mammalian cells has previously been studied using mathematical
modelling [3]. Polyamine metabolism in T. brucei has a number of
key features that distinguish it from polyamine metabolism in
mammals. The major differences lie in the specificity of
metabolites and enzymes as well as the associated regulation
patterns. Most notably, the enzyme s-adenosylmethionine decar-
boxylase (AdoMetDC) is activated through dimerisation with an
enzymatically inactive homologue termed prozyme. Moreover,
spermidine (Spd), in addition to its plethora of other cellular roles
(e.g. serving as an important inducer for the compact form of
DNA), in trypanosomatids, is linked to two molecules of
glutathione to yield the redox active metabolite trypanothione,
T(SH)2, which is a compound critical for trypanosome viability
and virulence.
Trypanosomes are sensitive to inhibition of the polyamine
pathway. For example, it has been shown that trypanosomes
depend on Spd for growth and survival, which ceases when the
level of Spd drops below a certain threshold [4]. There is therefore
considerable therapeutic potential in compounds that disrupt
polyamine biosynthesis. The suicide inhibitor eflornithine (difluor-
omethylornithine, DFMO) kills trypanosomes by irreversibly
interacting with ornithine decarboxylase (ODC) leading to
diminished polyamine levels. DFMO is now the first line treatment
used in HAT therapy. Inhibitors of AdoMetDC [5] have also been
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shown to be potently trypanocidal. These features have ensured
that the polyamine pathway in T. brucei has been subject to
investigation and details are available for enough of the enzymes to
allow a mathematical model to be constructed. A recent attempt to
model trypanothione (T(SH)2) metabolism in Trypanosoma cruzi (T.
cruzi) [6] also points to the value in modelling of this branch of
metabolism in trypanosomatids.
Dynamic behaviour of complex biological systems is not
deduced easily from collective descriptions of its individual parts,
requiring instead a systematic approach with advanced computa-
tional technology. Mathematical modelling offers a route to
achieve a system-level understanding [7,8]. In the context of
biological systems, mathematical models of metabolism allow
improved understanding of the contribution of individual enzymes
to the larger system. This can be achieved by studying the rates at
which system components interact and physical laws that govern
the reactions. Good models enable interpretation and predictions
about the consequences of pathway perturbation that can
supplement or even replace in vivo or in vitro experiments. Without
a reliable model, it is difficult to elucidate how complex properties
of dynamic systems arise from nonlinear enzymatic interactions.
In this paper, we develop the first kinetic model of polyamine
metabolism in blood-stream form T. brucei, derived from published
information related to system components and their interactions.
We are interested in seeking a model to reproduce what has
already been observed and also to make predictions about the
system to suggest future experiments and guide drug design. Since
mathematical models are manipulable, the mechanisms underly-
ing the metabolic regulation of polyamine biosynthesis can be
evaluated in silico. This kinetic model aims at understanding the
effectiveness of the anti-trypanosomal drug DFMO in detail and
examining other polyamine enzymes as potential targets for anti-
trypanosomal chemotherapy.
Results
As this is the first model of polyamine metabolism in T. brucei,
we shall summarise the main points from the the model design
procedure before presenting the simulation results of the kinetic
model. More details on the construction of the model are given
under Materials and Methods.
A detailed schematic representation of the trypanothione
metabolic network is depicted in Figure 1. This diagram indicates
the complex interconnections between the main pathways,
composed in parallel, which comprise the network. These are
the polyamine biosynthetic pathway for the production of Spd, the
glutathione biosynthetic pathway for the production of glutathione
and pentose phosphate pathway for the production of NADPH
mediating the reduced trypanothione redox cycle from oxidised
trypanothione disulfide. Spermine, which is a critical polyamine in
mammalian cells, is not taken into account due to its negligible
role in T. brucei [9–12]. Here we study the contribution of the
polyamine biosynthetic pathway to regulation of the total
trypanothione contents (the summation of both reduced and
oxidised trypanothione, TSHtot for short). In T. brucei the lack of a
classical arginase [13] has led to the identification of ornithine
(Orn) uptake from blood as the main mechanism to accumulate
this metabolite, serving as the only source for intracellular Orn in
our model. Metabolites and enzymes constituting the polyamine
pathway are emphasised with bold type in Figure 1.
Model development involved converting the reaction scheme of
interest in Figure 1 into a set of ordinary differential equations
(ODEs). In our model the polyamine biosynthetic pathway is
described mathematically by eight ODEs, which associate the
changes in concentration levels of system components with the rate
equations of enzymatic reactions involved. Some practical
considerations had to be taken into account when designing the
structure of the model in order to study this pathway in isolation
from the entire network.
Michaelis-Menten kinetics (for one substrate) has been used to
model enzymatic velocities of the MTA recycling enzyme
(MetRcy) and the transporter of exogenous Met (MetPt).
Michaelis-Menten kinetics with two substrates (rapid equilibrium
random bi-bi mechanisms) has been applied for the enzymes SpdS
and MAT. More complex mechanisms have been employed for
ODC, exogenous Orn uptake (OrnPt), AdoMetDC, TSHSyn and
TSHCpt to which standard Michaelis-Menten kinetics are not
sufficient to explain their behaviour. By comparing experimental
data with model predictions, we iteratively refined the mathemat-
ical representations of enzyme kinetics to render the model
satisfactory.
The incomplete knowledge of parameter values makes param-
eter estimation a necessary step prior to dynamic simulations. In
our study, simultaneous fitting against both the physiological
steady state and in vivo DFMO-mediated polyamine inhibition
reported by Fairlamb et al. [11] was applied to tune the unknown
parameters of the given model structure. DFMO-induced
perturbation is the most comprehensive data source available for
training the model (inhibition profiles being given for 6 out 8
metabolites of the pathway in T. brucei). Gene perturbation
measurements on ODC [14], SpdS [14,15], prozyme [16],
AdoMetDC [16,17] and trypanothione synthetase [18], which
were not used for training the model, are then employed as
validation data to evaluate the given model structure.
It is important to point out that this modelling activity is not
only challenged by the lack of prior knowledge, i.e. several kinetic
parameters are absent, but also by the fact that experimental
observations involve different trypanosome strains grown in
different conditions - work by Fairlamb et al. was from
trypanosomes grown in rats whilst other gene-perturbation
experiments involved in vitro cultivated strains. Inevitably,
therefore, absolute quantification of metabolite levels which is
strain and growth condition sensitive cannot emerge from such
limited studies, although the general trends in quantification are
conserved.
Model training
The ‘best’ set of parameter estimates from simultaneous fitting
against both the steady-state and DFMO-perturbed profiles is
reported in Text S1. Details on parameter estimation are given in
the Model Calibration section of Materials and Methods. Model
metabolites simulated with the ‘best’ set of parameter estimates
reached a steady state after less than the simulation time period of
two days and maintained it until the end of day 6. A good match
between steady-state levels of polyamine metabolites from model
predictions (termed the basal condition) and the reference data is
shown in Table 1. We further investigated model sensitivity to
different initial concentrations of pathway metabolites (varied by
up to+80% of the estimated initial values reported in Table S1).
We found that the behaviour of these model variants converged to
almost the same basal condition over a simulated time span of 4
days, indicating good stability (see Figure S1).
Model simulations of DMFO induction over an interval of
48 hours show good agreement with experimental data in terms of
both exact values and transient changes in the metabolite
concentrations, as shown in Figure 2. A drastic decrease of Put
was captured accompanied by a decrease in Spd. AdoMet was well
fitted, and remained unchanged as observed in [14]. This may be
Modelling of Polyamine Metabolism in T. brucei
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attributed to the fact that free-form AdoMetDC is insensitive to
the reaction product dAdoMet as indicated by the high value of
970.6 mM predicted for the product inhibition parameter, which
agrees with the hypothesis made in [19]. An increase of Orn was
observed within the first 12 hours of DFMO treatment, followed
by attainment of an accurate steady state. Dynamics of TSHtot
was also well captured compared with the measurements reported
for the reduced trypanothione. Note that when plotting the time
course of polyamines under perturbed conditions, the basal
condition acts as the initial status for the simulation of DFMO-
treated model, which also applies to model simulation under other
perturbed conditions investigated below.
Figure 1. A detailed graphical representation of total trypanothione metabolism. Edges represent chemical conversions between model
components with arrows indicating reaction directionality. Metabolites and reactions constituting the polyamine biosynthetic pathway that are
considered in this model are emphasised with bold type, with time-variant metabolites shown in green and constant metabolites shown in pink.
Enzymes catalysing each active elementary step in the pathway are denoted with blue boxes. The remaining modules of the network shown in grey
are not modelled but help gaining an overall picture of the metabolism. Abbreviations of polyamine metabolites: Met, methionine; AdoMet, S-
adenosylmethionine; dAdoMet, decarboxylated AdoMet; MTA, methylthioadenosine; AdoHcy, S-adenosylhomocysteine; Orn, ornithine; Put,
putrescine; Spd, spermidine; TSHtot, total trypanothione;Metexg , exogenous methionine; Ornexg, exogenous ornithine. Abbreviations of intra-cellular
polyamine enzymes: MetPt, Met uptake enzyme; MAT, AdoMet synthase; AHS, methyltransferase; AdoMetDC, AdoMet decarboxylase; MetRcy, Met
recycling enzyme; OrnPt, Orn uptake enzyme; ODC, Orn decarboxylase; SpdS, Spd synthase; TSHSyn, TSHtot synthesis catalyst; TSHCpt, TSHtot
consumption catalyst.
doi:10.1371/journal.pone.0053734.g001
Table 1. Basal condition of polyamine concentrations.
Met AdoMet dAdoMet Orn Put MTA Spd TSHtot
from Model (mM) 3341.5 20.3 26.2 86.2 180.7 20 2049 340
from refs. (mM) [11] 3978 19 9 43 517 20 2069 340
doi:10.1371/journal.pone.0053734.t001
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Model validation
Comparison between model predictions using estimated
parameter values and independent data sets obtained from distinct
states of the system allows assessment of model use. To this end,
data from available drug treatment and gene-knockdown pertur-
bation experiments on ODC [14], SpdS [14,15], prozyme [16],
AdoMetDC [16,17] and trypanothione synthetase [18] are used as
validation data. When simulating the model for each of the
perturbation experiments, the wild-type value of the maximum
velocity for each individual enzyme (VEmax with E representing the
specific enzyme name) is replaced with an exponential decay
function of the form of VEmax
:e{lE
:t in the corresponding rate
equations, which aims to mimic the inhibition of individual
enzymes over time (t). An exponential decay constant, lE , was
derived for individual instances by parameter fitting according to
the given inhibitory profiles of corresponding enzymes. For all
other kinetic parameters, the values were fixed at those reported in
Text S1.
Model predictions on the consequences of ODC
knockdown
DFMO is used to treat HAT and acts by inhibiting ODC with
knock on effects on polyamine production, for example, reducing
Put and Spd. As shown in Figure 3, our model replicated the
reduction in concentrations of Put, Spd and TSHtot over 48 hours
of model simulation where ODC activity is reduced by 90% within
24 hours of induction (as specified in [14]). dAdoMet serves to
provide the aminopropyl group in Spd production which
accumulates dramatically, while AdoMet is unchanged as reported
in [14].
Model predictions on the consequences of SpdS
knockdown
Spd plays multiple roles in trypanosomes including a critical
role in producing the redox reactive thiol metabolite trypa-
nothione (T(SH)2), which underlines the sensitivity of trypano-
somes to the loss of Spd through reduced capability to maintain
cellular redox. SpdS has been validated as a potential drug target
in T. brucei [14,15]. Xiao et al. [14] observed that after 6 days of
RNAi-mediated Spd depletion (SpdS activity knocked down by
90% within 2 days of induction), Spd and T(SH)2 decreased to
20% and 5% of the uninduced controls. Our model predicted a
similar trend in changes in concentrations, namely that Spd and
TSHtot are reduced to 17% and 6% of the controls, as shown in
Figure 4C and Figure 4D. No significant changes were found for
AdoMet and our model predicted this as well for this metabolite
(see Figure 4A).
Figure 2. Time-series simulation of DFMO effects on polyamine levels compared with experimental data. Lines without symbols, model
predictions; lines with symbols, experimental observations from [11]. The maximum velocity of ODC was modelled as a time-dependent variable, with
the activity decreased by more than 99% within 12-hour of treatment with DFMO. AdoMet dynamics observed by Xiao et al. [14] were adopted. Error
bars are presented where appropriate data was available in the original papers.
doi:10.1371/journal.pone.0053734.g002
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Put is an interesting metabolite regarding its response to SpdS
down-regulation. Xiao et al. reported a 45% decrease in Put
concentration over 3 days after SpdS depression. Taylor et al. [15]
also showed that, within 3 days, repressing SpdS to just 5%
compared to wild type caused a 60% decline in Spd contents but,
unexpectedly, no significant build up of Put was found. In T. brucei
therefore, cellular overproduction of Put is avoided, possibly as
excessive Put can elicit oxidative stress as reported in mammalian
cells [20,21].
One refinement we made during the model building procedure
was to introduce a term reflecting the plausible regulation of SpdS
on ODC activity (defined in Equation 1 in the Model Descriptions
section of Materials and Methods) which serves to prevent
excessive Put accumulation in the case of SpdS perturbation, as
demonstrated in Figure 4B. We observed that when this term is
removed from the model while keeping the remaining parameters
unchanged, a 90% knockdown of SpdS leads to a dramatic
buildup in Put level (see Text S4). Inclusion of this regulatory term
enables the model to simulate experimental observations. It will
now be of interest to determine the biological basis of this
regulation.
Model predictions on the consequences of AdoMetDC
knockdown and prozyme knockout
AdoMetDC has already been validated as a drug target in T.
brucei. Loss of AdoMetDC or prozyme was observed to lead to
decreases in Spd and T(SH)2 and to cell death [16]. In our model,
simulations of prozyme knockout (over a simulated time span of 4
days with a complete removal of the ligand-binding form of
AdoMetDC) and AdoMetDC knockdown (over a simulated time
span of 6 days with a 70% down-regulation of total AdoMetDC
concentration within 2 days of induction, as specified in [16]) both
resulted in a large increase in Put levels and substantial reduction
in Spd and TSHtot. Simulation of the time-dependent effects on
polyamine levels of Put, Spd and TSHtot, induced by AdoMetDC
knockdown and complete prozyme knockout are reported in
Figure 5A–5C. An 80% reduction due to prozyme knockout
versus 65% reduction from AdoMetDC knockdown for Spd and a
94% reduction due to prozyme knockout versus 70% reduction
from AdoMetDC knockdown for TSHtot, were seen. These results
are in good agreement with the tendencies described by real
experimental observations [16].
We further compared the resulting TSHtot content when the
same degree of inhibition (70% knockdown applied to total
AdoMetDC concentration) was applied to ODC. Our model
predicted a relatively lower TSHtot level at the end of the
Figure 3. Time-series simulation of ODC inhibition on polyamine levels compared with observed values. Lines without symbols, model
predictions; lines with symbols, experimental observations from [14]. The maximum velocity of ODC was modelled as a time-dependent variable
during the simulation with lE equal to 0.0016, where the ODC activity was decreased by 90% within 24 hours of RNAi induction. Error bars are
presented where appropriate data was available in the original papers.
doi:10.1371/journal.pone.0053734.g003
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simulated time span of 4 days from AdoMetDC inhibition (70%
depletion) compared with that from ODC inhibition (40%
depletion), which agrees with [17] that AdoMetDC could be a
more promising chemotherapeutic target than ODC for T. brucei.
Additionally, a 70% AdoMetDC knockdown or prozyme knock-
out caused an almost full depletion of dAdoMet accompanied by a
6-fold increase in Orn while AdoMet remained constant. These
model predictions can be verified when the relevant experimental
data is available. Our model simulations also reveal that activity of
free-form (homodimeric) AdoMetDC (VAdoMetDCO ) is 0.03% of the
activity of heterodimer AdoMetDCDprozyme (VAdoMetDCL ), which
is consistent with the experimental observations [16] that the
former is as low as v0:1% of the latter, indicating that prozyme
reacting with AdoMetDC is a limiting factor for AdoMetDC
activity.
Our model has also been validated on the consequences of
inhibiting AdoMetDC activity by a specific inhibitor MDL73811
(59- {[(Z)-4-amino-2-butenyl]methylamino}-59-deoxyadenosine).
When AdoMetDC activity was almost completely inhibited (to
2% of control value within 1 hour of administration), a modest
33% decrease in Spd was observed by 4 hours post-administration
of MDL73811 [17]. Our model predicted a similar 30% reduction
in Spd over a simulated time span of 4 hours in response to the
strong AdoMetDC down-regulation (via reducing total Ado-
MetDC enzyme concentration ½AdoMetDCT to 2% of the
control value) and a 20% depletion in TSHtot was predicted.
Simulation results are depicted in Figure 5D.
One other refinement we made during the model construction
procedure was to present the ODC-catalysed reaction with
reversible kinetics. This implementation led Put to plateau in
response to perturbations of AdoMetDC and prozyme. However,
in the case of SpdS perturbation, simply modelling the ODC-
catalysed reaction reversibly (without the addition of the postulat-
ed regulation between SpdS and ODC) indeed helped to alleviate
excessive accumulation of Put, but a 20-fold increase in Put
contents was still observed over a simulated time span of 6 days,
indicating that the additional regulation of SpdS on ODC is
essential regardless in this case. Refer to Text S4 for more details.
Model predictions on the consequences of TSHSyn
knockdown
Trypanothione synthase (TryS), which catalyses production of
the reduced trypanothione, T(SH)2, from Spd and glutathione
has been recognised as a good drug target for trypansomes [18]. It
has been the focus of anti-trypanosomal research, owing not only
to its significant role in trypanosomal viability but also its
capability in regulating the levels of polyamines, glutathione and
glutathione-spermidine conjugates. In our model, this enzyme is
represented as TSHSyn and a one-step production of total
trypanothione from Spd is assumed (as stated in the Model
Figure 4. Time-series simulation of SpdS inhibition on polyamine levels compared with observed values. Lines without symbols, model
predictions; lines with symbols, experimental observations from [14]. The maximum velocity of SpdS was modelled as a time-dependent variable with
lE equal to 0.0016. Error bars are presented where appropriate data was available in the original papers.
doi:10.1371/journal.pone.0053734.g004
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Descriptions section of Materials and Methods). Ariyanayagam et
al. [18] reported that, within 3 days of TryS inhibition, TryS
activity decreased 10-fold, giving rise to a 85% reduction in
T(SH)2 at the end of 8 days of RNAi induction, whereas the
reactants of the reaction, Put and Spd, are not significantly
increased. Despite the absence of glutathione in the model,
knockdown simulations of TSHSyn (following the reported
inhibitory profile of TryS) predicted a good match with the
measured concentration changes of Put (no profound changes
predicted) and T(SH)2 (a 80% decrease in total trypanothione,
TSHtot, predicted) at the end of simulation duration of 8 days
(illustrated in Figure 6).
However, our model predicted a 10-fold increase in Spd level,
which contradicts the measured dynamics. We postulate that this
may result from the exclusion of glutathione in the model, which is
found to accumulate markedly over 8 days of TryS inhibition in
our simulation study. A potential elevation in Spd levels could be
averted if it reacts with increased glutathione levels to produce
TSHtot. In the absence of quantitative inclusion of glutathione in
our model, Spd was unconstrained to be rapidly increased. We
tested this hypothesis by combining the above TSHSyn inhibition
with an increased utilisation of Spd (modelled through reduction
in Spd production rate to 5% of the uncontrolled level at the end
of 3 days). The model predicted a 30% drop in Spd accompanied
with a considerable (90%) reduction in TSHtot, supporting the
possibility that Spd levels may be regulated by the interaction with
glutathione. When adequate kinetic information becomes avail-
able regarding glutathione kinetics and intermediate metabolites in
T. brucei, integration of the polyamine model with glutathione
biosynthesis would be useful for improving quantitative predictions
on inhibition consequences.
We also examined the consequences of knockdown of TSHCpt
(catalysing the sink reaction of total trypanothione, TSHtot) and
found that inhibition of TSHCpt increased the concentration level
of total trypanothione (shown in Figure S2) but no dramatic
changes on other metabolites of the pathway were seen.
Figure 5. Time-series simulation of AdoMetDC inhibition on polyamine levels compared with observed values. Lines without symbols,
model predictions; lines with symbols, experimental observations from [16] for (A) to (C) and [17] for (D). In (A) to (C), during knockdown (KD)
simulations, total AdoMetDC concentration ([AdoMetDCT ]) was modelled as a time-dependent variable with lE equal to 0.0004 to represent the
70% activity down-regulation within 2 days of induction; during knockout (KO) simulations, the factor 1{b representing the percent of the complex
AdoMetDC|prozyme taking up the total enzyme AdoMetDC is set to zero to represent full prozyme removal. In (D), MDL effects on Put and Spd
dynamics were plotted. During the simulation, total enzyme concentration of AdoMetDC was modelled using a exponential decay function with lE
set to 0.07 to mimic a 98% knockdown within 1 hour of induction as specified experimentally. Error bars are presented where appropriate data was
available in the original papers.
doi:10.1371/journal.pone.0053734.g005
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Discussion
Sensitivity analysis
Sensitivity analysis describes changes of metabolite concentra-
tions as result of changes in model parameters. We examined
model sensitivity properties by running the model with the
maximum velocity (VEmax) of key pathway enzymes varied
independently by +10% of the nominal values. The model then
evolves to a new steady state over a simulated time span of 6 days.
Changes of maximum activities of enzyme MAT and MetPt
resulted in a global effect on the system, whereas some parameters
influenced specific metabolites; for example, changes of TSHSyn
led specifically to changes of Spd and TSHtot and the function of
TSHCpt is limited to TSHtot only. The other input to the model,
OrnPt, also showed an impact on Orn, Put and TSHtot. With this
analysis, we observed that when ODC is inhibited, Orn built up
rapidly over 2 days leading to a new steady state, which is
proportional to the degree of knockdown applied to ODC
(illustrated in Figure 7). This figure may explain why reversible
inhibitors of ODC are not successful in killing trypanosomes as the
extensive increase in Orn concentration (almost 7.5 times of the
normal Orn value) will out-compete the reversible inhibitors
interacting with ODC. The binding of the enzyme with
irreversible inhibitors can however prevent competition from the
substrate, but the inhibitors have to be sufficiently potent to cause
apparent loss of TSHtot content.
We compared the changes in TSHtot dynamics over a simulated
time span of 5 days. Individual enzymes were subject to a 90%
knockdown within 24 hours of simulation. These enzymes
included ODC, SpdS, prozyme, MAT, OrnPt, MetPt and
TSHSyn - enzymes involved in de novo synthesis of total
trypanothione. Figure 8A indicates that a 90% knockdown of
each enzymes led to decreased TSHtot, with levels dropped to less
than 10% of the unperturbed level at the end of simulation span.
MetPt, MAT, prozyme and OrnPt exhibit a much stronger
inhibitory effect on TSHtot than ODC and SpdS. TSHSyn
displayed a faster converging trajectory after 48 hours of
simulation and a more complete depletion of TSHtot than all
other enzymes.
We further analysed TSHtot concentration changes (at the end
of a simulated time span of 5 days) with respect to different
knockdown levels for individual enzymes. Figure 8B indicates that
when activity knockdown is more than 70%, TSHSyn has the
strongest inhibitory effect on TSHtot, whereas when the knock-
down is less than 70%, MAT, MetPt, Prozyme and OrnPt exert
the most effective control on TSHtot reduction. Under all
scenarios, ODC and SpdS displayed a relatively weaker inhibitory
impact on TSHtot. We observed that a 70% loss of ODC and
SpdS led to the same effect as a 60% loss of TSHSyn or a 50%
reduction of MAT, MetPt, Prozyme or OrnPt, indicating that to
achieve the same level of TSHtot depletion (70%), the knockdown
strength required for different enzymes should follow
ODC,SpdSwTSHSynwMAT ,MetPt,Prozyme,OrnPt. This
could point to the enzymes MAT, MetPt, Prozyme and OrnPt
as good potential drug targets, which result in the depletion of
TSHtot with only small perturbations.
Combination chemotherapy for T. brucei
Enzymes responsible for polyamine biosynthesis are proven
drug targets. Simulations generated by our model indicate that
strong down-regulation of individual enzymes including ODC,
prozyme, SpdS and TSHSyn lead to reductions in TSHtot levels,
demonstrated to be potential targets for drug design.
The use of mathematical models not only provides a
mechanistic understanding but can also drive new and more
effective experiments. Combination chemotherapy for African
sleeping sickness is attractive as it offers the potential for lower
doses of drugs and reduced risk of resistance emerging for
individual compounds. The additional requirements for regulatory
approval of combination therapies however makes de novo
production of combination therapies difficult, but it is worth
noting that for HAT it was possible to introduce a DFMO-
nifurtimox combination therapy (NECT) which has advantages
over DFMO monotherapy alone [22,23]. Metabolomics analysis
did not indicate a role in polyamine pathway inhibition by
nifurtimox [13], however the precedent to introduce, rapidly, a
combination partner to work alongside DFMO has been set.
Figure 6. Time-series simulation of TSHSyn inhibition on TSHtot
level compared with observed values. Lines without symbols,
model predictions; lines with symbols, experimental observations from
[18]. During the simulation, the maximum velocity of TSHSyn was
modelled as a time-dependent variable using the exponential decay
function with lE set to 0.00045. Percentage changes of Put and T(SH)2
at discrete time points over a simulated time span of 8 days were
extracted from [19] and normalised to the basal conditions of respective
metabolites. For Put, only the percentage change at the end of the
simulated time span was shown, since percentage changes for this
metabolite over other time points were not reported in [19].
doi:10.1371/journal.pone.0053734.g006
Figure 7. Orn dynamics over 2 days after ODC activity
depression. During the simulation, the maximum velocity of ODC
was modelled as a time-independent constant by multiplying the
normal value by the percentage amount.
doi:10.1371/journal.pone.0053734.g007
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Our investigation into combination therapies against T. brucei
focused on a group of enzymes (denoted as Group A) that, when
used in tandem with weak perturbation of other enzymes (denoted
as Group B), result in a similar or even more potent inhibitory
effect than when these other enzymes alone (Group B) are strongly
perturbed. Knowledge gained from this kind of combination
therapeutic schemes on how potent a compound needs to be
perturbed in order for it to be an effective drug target helps look
for alternative solutions when some enzymes cannot be strongly
inhibited. We found through model simulations that MAT and
OrnPt are good candidates to be taken as Group A enzymes. The
following section provides a detailed analysis of the results.
Studying effects of inhibiting pairs of enzymes on TSHtot, as
illustrated in Figure 9A, shows that a combination of a 70%
knockdown of enzyme MAT, prozyme or OrnPt with a weak
(10%) down-regulation of ODC produces a similar effect on
TSHtot depletion as when ODC is almost completed removed. In
conjunction with a 50% loss of MAT, prozyme or OrnPt, a weaker
TSHtot inhibition is obtained at the end of a simulated time span,
but a faster depletion rate is displayed over the first 24 hours of
inhibition than using a 90% ODC knockdown alone. A 10%
prozyme depression (Figure 9B), together with a 50% down-
regulation of MAT or OrnPt decreased TSHtot concentration to
the same level at the end of a simulated time span as when only a
50% prozyme depression was applied. In conjunction with a 70%
MAT or OrnPt down-regulation, the same 10% prozyme
knockdown decreased TSHtot to the same extent as a 90%
prozyme knockdown alone. Furthermore, combining the same
10% prozyme knockdown with a 70% loss of ODC resulted in the
same degree of TSHtot depletion as lower-level joint perturbations
(50%) with MAT or OrnPt. In individual cases, combining a 10%
knockdown of ODC or prozyme with a 70% TSHSyn inhibition
depleted TSHtot to the same amount as when the respective
enzyme is perturbed by 90%, but with a slower inhibitory
trajectory compared to combination therapies with MAT and
OrnPt.
Figure 9C and 9D support our previous conclusion that
TSHSyn and prozyme alone are capable of adequately removing
TSHtot when they are subject to a sufficiently strong deactivation.
As indicated in Figure 9C, the combination of a down-regulation
of 70% in prozyme with a 70% depression of enzyme MAT
produces the same temporal dynamics and final depletion of
TSHtot as a 90% prozyme knockdown alone. The maximum level
of TSHtot depletion occurs when prozyme (knocked down by 50%
or 70%) is combined with a more potent 90% MAT down-
regulation. Combining a 70% loss of prozyme with a medium to
strong OrnPt perturbation can lead to a similar level of TSHtot
depletion, but not as strong as exerted by MAT. In Figure 9D,
when TSHSyn is down-regulated by more than 50%, down-
regulation of MAT or OrnPt by as much as 70% is required in
tandem to obtain the same level of TSHtot depletion as a 90%
TSHSyn down-regulation alone. We observed that even though
combination therapies for TSHSyn and prozyme result in
approximately the same level of TSHtot depletion at the end of
the simulated time span, they exhibited faster inhibitory trajecto-
ries, giving rise to more TSHtot removal at earlier stages (the first
2–3 days of simulation span, see Figure 9D). In both cases,
combining a 70% knockdown of prozyme or TSHSyn with a 70%
OrnPt down-regulation led to the same final TSHtot level, but
with slower temporal dynamics than other strategies over the same
duration.
As indicated in Figure 8, MAT and MetPt knockdown both
result in almost the same depletion pattern for TSHtot. As such,
MetPt related perturbation was found to be applicable to the
perturbation experiments carried out here in the same way as
MAT. It has been verified that a constant supply of Met is
imperative for trypanosomal cell growth [24,25], supporting the
credibility of the predictions made by this model. Similarly, the
results observed for ODC are applicable to SpdS, however SpdS
displayed a better inhibitory effect than ODC (likely due to the
regulatory link predicted for the enzymes) but still not comparable
with that from MAT or OrnPt.
The combination chemotherapeutic strategy suggests that
enzymatic reactions of AdoMet production and Orn uptake,
catalysed by MAT and OrnPt, respectively, are key regulatory
points in the pathway. When used alone or in tandem with weak
down-regulation (i.e. 10%) of other enzymes, a moderate
perturbation (i.e. 50%) of MAT and OrnPt exhibited a strong
Figure 8. Studies of changes in TSHtot concentration under different perturbation scenarios. In (A) time-series TSHtot concentration
values are calculated over a simulated time span of 5 days subject to a 90% decrease in individual enzyme velocities. A 90% knockdown of AdoMetDC
enzyme concentration and a 90% prozyme knockdown were found to follow a similar pattern of TSHtot dynamics, and only prozyme inhibition is
shown. In (B) TSHtot concentration values at the end of the simulated time span (5 days) are calculated subject to various degrees of knockdown (KD)
for individual enzymes. In both figures, the percentage of TSHtot concentration under perturbed (½TSHtotKD) and normal (½TSHtotNom) conditions is
plotted. In all cases, the maximum velocity of each enzyme is a time-dependent variable subject to specific inhibition within 24 hours of simulation.
doi:10.1371/journal.pone.0053734.g008
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inhibitory impact on the total trypanothione production, with the
former being more effective than the latter, in particular, when
MAT knockdown is used in conjunction with medium or strong
perturbation of prozyme and TSHSyn. The regulation of
polyamine synthesis via MAT or OrnPt is likely to be a good
chemotherapeutic target.
Relation to T. cruzi model
Our polyamine model complements a recent attempt at
modelling trypanothione (T(SH)2) metabolism in the related
parasite T. cruzi [6]. The T. cruzi model focuses on the glutathione
synthesis branch and the redox cycle of T(SH)2. Polyamine
synthesis, which is the focus of this work, is not included. Our
simulation results (Figure 8) agreed with observations made in the
T. cruzi model that at 80%–100% down-regulation, most of the
involved enzymes are found to be essential for parasite survival. In
particular, TSHSyn (TryS in the T. cruzimodel) has to be inhibited
by 70% to sufficiently deplete total trypanothione contents which
is consistent between the two models.
Both studies attempt to identify promising therapeutic strategies
and this issue is viewed from the aspect that ‘‘suitable drug targets
should be enzymes for which low pharmacological inhibition have
a high impact on pathway function [6]’’. Pathway enzymes in the
T. cruzi model were ranked according to control efficiency of
individual enzyme and simultaneous inhibition of those enzymes
with top scores were recommended as being good candidates for
multi-target strategies, whereas in our T. brucei model, different
combination therapies of key pathway enzymes were simulated
and time-dependent concentration changes were measured against
total trypanothione contents (Figure 9), providing us with a direct
comparison among alternatives. We would like to take this work
further by merging these two models to evaluate the perturbation
effect on total trypanothione contents when the good targets
identified from the respective work are jointly used. However, this
is challenged considerably not only by the differences in parameter
values but also the kinetic reactions specific to individual
organisms. For example, the cysteine uptake reaction that was
not modelled in the T. cruzi model has proven to be critical for
trypanosomal survival in T. brucei [25]. Compared with T. brucei, T.
cruzi lacks ODC activity and relies on Put uptake from the
extracellular medium. Additionally, both organisms can synthesise
Spd de novo from dAdoMet and Put, but T. cruzi also has the
capability to assimilate exogenous Spd (this uptake reaction was
modelled as the only source of endogenous Spd in the T. cruzi
model). Integration of these models could further assist in gaining
Figure 9. Studies of combination chemotherapeutic regimens. Percentage of TSHtot concentration under perturbed (½TSHtotKD, over a
simulated time span of 5 days) and normal (½TSHtotNom) conditions. In individual model simulations (A) and (B), a 10% enzyme knockdown (KD) of
ODC and prozyme is applied in conjunction with down-regulation of other key pathway enzymes and the simulation results from individual and
combined perturbations are compared. In (C) and (D), the inhibitory effects on TSHtot were examined for combinations of medium to strong
depression of prozyme and TSHSyn, respectively, with different levels of knockdowns of other enzymes. In all cases, the maximum velocity of each
enzyme is a time-dependent variable subject to specific inhibition within 24 hours.
doi:10.1371/journal.pone.0053734.g009
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an in-depth understanding of the overall metabolic system in
trypanosomes.
Conclusion
Here we present the first model of a second branch of
metabolism, the polyamine pathway, which can be linked to an
existing model of glycolysis via the second route of glucose
metabolism in T. brucei, the pentose phosphate pathway that
creates NADPH, which is the ultimate source of electrons required
to form the reduced trypanothione (T(SH)2) and the cell’s
primary reactive thiol species.
This mathematical model provides continuous and determinis-
tic descriptions of system dynamics by applying ODEs, which has
previously been employed to model quantitatively the glycolysis
pathway in bloodstream-form T. brucei [26]. An alternative
approach to modelling metabolic systems is via structural
modelling. Structural modelling takes the stoichiometry and
reversibility of chemical reactions as the only inputs, which is in
contrast to kinetic modelling where precise information of involved
enzymatic rate equations and associated parameter values is a
prerequisite. Structural modelling is a relatively straightforward
process and because the knowledge required for this approach is
primarily the stoichiometry of a system, the drawback is the
limited predictive power in studying system dynamics that involves
manipulating enzymatic mechanisms. Therefore, structural mod-
elling is often regarded as a precondition for kinetic modelling.
Our modelling activities focused on studying the effectiveness of
DFMO, the first line drug licensed to target stage 2 HAT. Previous
work has generated a significant amount of information regarding
the network topology and kinetic analysis of many of the
enzymatic reactions has made kinetic modelling possible. Howev-
er, parameters for a significant number of the enzymes involved in
the pathway were unknown. Therefore it was necessary to
introduce assumptions and simplifications to the pathway were
required. Qualitative knowledge of the pathway guided the
assumptions made and optimisation-enabled dynamic simulations
were used to test how assumption-containing models performed
relative to outputs measured in experiments. Discrepancies
between model simulations and experimental observations
prompted a cyclic procedure of model design. The mathematical
formulation of the model equations together with the estimated set
of parameters faithfully reproduces most experimentally measured
properties of the pathway.
The model already offers opportunities to explore new strategies
for targeting this pathway in anti-trypanosomal drug design.
Combined down-regulation of key pathway enzymes offers an
effective chemotherapeutic strategy. Combination chemothera-
peutic studies revealed that most polyamine enzymes can influence
polyamine biosynthesis, but when targeted alone, high levels of
inhibition are required to inhibit the pathway sufficiently to kill
cells. Most importantly, reactions catalysed by enzyme MAT or
OrnPt appear to be critical control points of the pathway, with
MAT being preferable to OrnPt. Moderate disruption of MAT or
OrnPt, both in isolated and joint form, led to dramatic changes in
polyamine concentrations and total trypanothione contents. Our
study also shows that prozyme and TSHSyn could be used for
multi-target therapy but only when they are potently inhibited (at
least 50% knockdown) together with similar down-regulation of
MAT or OrnPt.
In general, enzymes or metabolites identified in parasites and
known to be absent from or significantly different in the
mammalian host were ideal targets for chemotherapy. In T. brucei,
MAT is insensitive to control by product inhibition of AdoMet but
mammalian isoforms of this enzyme are highly sensitive to
AdoMet. The function of MAT in linking inhibition of polyamine
synthesis to disruption of AdoMet metabolism and the differences
of MAT in host and parasites could make this enzyme a critical
drug target. T. brucei lacks arginase and depends on efficient Orn
uptake, which makes OrnPt an especially attractive drug target.
Certainly, a valid target should not only be lethal to parasites but
also be acceptably safe for human patients in long-term clinical
usage. Therefore, these potentially good drug targets have to be
further validated in terms of the therapeutic benefit and safety.
In conclusion, it has been necessary to include multiple
assumptions and simplifications to build a model of polyamine
metabolism in T. brucei because insufficient data was available to
produce a full description. Notwithstanding, the availability of
several datasets giving measurements of metabolite levels following
pathway perturbation has enabled us to adjust assumed param-
eters and simplifications in a way that allows reasonable
simulations of measured activity. The model has then been used
to make predictions on potential co-inhibition of different enzymes
of the pathway to inform possible strategies for combination
chemotherapy and can report on possible regulatory components
of the pathway which can now be approached experimentally.
The basic model description here can be further improved as new
information becomes available in T. brucei on specific kinetic
parameters of enzymes in the pathway and measured metabolite
levels under different perturbed conditions.
Materials and Methods
Considerations for model construction
van Riel [27] argued that many attempts of computational
modelling pursue realistic large-scale complex models, but very
often simplified models are feasible and at least as valuable in
understanding the essential features of biological systems. The
following considerations were made in order to study the
polyamine pathway in isolation from the entire network as
presented in Figure 1.
Firstly, the involvement of the trans-methylation branch
(responsible for the production of cystathionine via homocysteine)
was limited to the first step describing the conversion of AdoMet
into AdoHcy (S-adenosylhomo-cysteine). As observed in [28,29],
metabolic products of trans-methylation reactions (i.e homocyste-
ine and cystathionine) are mostly secreted from trypanosomal cells,
which leave their contributions in polyamine biosynthesis and
regulation very minimal. Parasitic T. cruzi and Leishmania species
lack the enzyme of Met synthase, which catalyses the Met
production from homocysteine; however, debate remains as to
whether homocysteine can be converted to Met in T. brucei [30].
Goldberg et al. [31] also suggested that, even though homocys-
teine remethylation may exist in T. brucei, as most trans-sulfuration
metabolites are secreted from trypanosomes, any homocysteine
recycled to Met will not be significant. AdoHcy, which is toxic if
accumulated in cells [28], was also observed to remain unchanged
under perturbed conditions in T. brucei, i.e. during 36 hours of
DFMO treatment [29], and thus is treated as a constant
metabolite in our study.
Secondly, we excluded glutathione biosynthesis and related
reactions from consideration and modelled the biosynthesis of
TSHtot with a single-step reaction from Spd, catalysed by a
synthetic enzyme, named TSHSyn. In T. brucei, the reduced
trypanothione, T(SH)2, is synthesised in two steps. First, a single
molecule of Spd is combined with glutathione to generate a
glutathione-spermidine conjugate (not shown in Figure 1). This is
followed by the addition of a second glutathione creating the
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reduced trypanothione from. It has been reported that both
synthetase and amidase activity are associated with biosynthesis of
the reduced trypanothione in T. brucei [32] as well as in Leishmania
parasites [33] and Crithidia fasciculata [34]. The conflicting activities
of synthetase and amidase allow for a bidirectional response
between the involved metabolites, which may serve to modulate
intracellular levels of these metabolites without additional biolog-
ical processes (i.e protein synthesis or degradation of existing
metabolites). There is however very limited information for
enzyme kinetics of the intermediate steps of glutathione biosyn-
thesis and the regulation mechanism between synthetase and
amidase has not yet been precisely characterised in T. brucei. The
approximate description of TSHtot biosynthesis reduces the
degrees of freedom and diminishes the impact of unknowns in
the model simulations. In the rate equation of TSHSyn, a
regulatory term for the reaction product TSHtot is included to
reflect the self-regulation ability of Spd and TSHtot, as if they are
modulated by the amidase activity.
Finally, the link between TSHtot and the remaining system (i.e.
the pentose phosphate pathway in the grey box in Figure 1) was
modelled as a black box (refer to [35] for a case study). Black-box
modelling is a popular approach for modelling chemical processes
that lack physical insight or are highly abstract [36,37]. The key of
this approach is to approximate input-output dynamics of the
involved metabolites. In our work, this is the relation between Spd
(input) and trypanosomal growth (output, proportional to the
concentration of total trypanothione, TSHtot). This modelling
strategy facilitates the practical construction of a useful model of
polyamine metabolism with predictive capabilities; this can only be
achieved when all intra-cellular metabolites are modelled as time-
dependent variables. Black-box structures are parameterised
descriptions, which can be approximated in the form of, for
example, power series polynomials and fuzzy logic. In this study, a
combination of a Hill equation and a linear decay function
proportional to the concentration of TSHtot is used to model this
reaction (details are given in the Model Descriptions section of
Materials and Methods). Inclusion of total trypanothione in the
model allows us to quantify explicitly the consequences of
polyamine interruption on cell growth arrest in the context of
the model.
A summary of iterative model design
In the standard approach (see [38,39] for details), an initial
model topology that approximates the input-output relationship of
the system is constructed, and then a parameter estimation process
is applied to match a particular dataset against model structure.
Once a candidate model is built in this way, it can be tested on
validation data, i.e. data not used in the parameter estimation step.
If the estimate-containing model demonstrates predictive power it
may be considered to be relevant in describing the underlying
processes. Where inconsistency emerges between model predic-
tions and experimental observations the model is refined and
iteratively evaluated against validation data.
Following the above system identification procedure, five
candidate models were generated, which share the same topology
but differ with respect to the mathematical representations of
enzyme kinetics. Refinements made throughout model construc-
tion were summarised in Table S2, where the final model
performed the best on both the estimation data and validation
data and its description form the basis of this paper.
Model descriptions
The polyamine biosynthetic pathway is described mathemati-
cally by eight ODEs (Table 2), each of which corresponds to a
time-dependent variable metabolite. The ODE model takes
exogenous methionine (Metexg) and ornithine (Ornexg) as the only
inputs, since T. brucei does not have an efficient mechanism for the
assimilation of exogenous putrescine (Put) and Spd, and relies on
de novo synthesis to acquire these two polyamines [15,40].
Concentrations of both external (Metexg and Ornexg in blood)
and constant (AdoHcy) metabolites are fixed at their physiological
levels.
Rate equations for individual enzyme-catalysed reactions, which
are displayed on the right hand side of the ODEs, are detailed
below.
ODC catalyses the initial step in the pathway leading to Put
production from Orn. ODC has an extremely short intra-cellular
half-life in mammals, reportedly 15 min to 1 hr, which is in
contrast to the more stable protein in T. brucei, which has a
turnover rate greater than 6 hrs. The reversible rate law was
applied to model ODC kinetics in the form below, which is subject
to weak product inhibition by Put and postulated correlation of
SpdS on ODC. Due to the lack of information on these two
parameters, we assumed the half-saturation constant KODCmPut to
have the same value as the known parameter KODCmOrn and we
analytically derived the equilibrium constant KODCeq from the
experimental observations of AdoMetDC RNAi induction and
prozyme knockout. Refer to Table S2 and Text S4 for more
information on these two parameters. When SpdS remains
uninduced, parameter lSpdS is zero and thereby the maximum
velocity of ODC becomes time-independent. Under SpdS
perturbations, a positive value has been deduced for parameter
lSpdS from the given inhibitory profile of SpdS deactivation to
mimic the temporal changes of SpdS activity over time and in this
case the maximum velocity of ODC becomes time-variant and
influenced by the activity changes of SpdS.
VODC~ ½Orn{ ½Put
KODCeq
 !
:
VODCmax
:e
({lSpdS
:t)
KODC
mOrn
1z
½Orn
KODC
mOrn
z
½Put
KODC
mPut
:(1z
½Put
KODC
iP
)
0
BBBB@
1
CCCCA ð1Þ
Table 2. Differential equations for the time-dependent
variables included in the model.
Variables Differential Equations
½Met d½Met
dt
~VMetPt{VMATzVMetRcy
½AdoMet d½AdoMet
dt
~VMAT{VAdoMetDCT
{VAHS
½dAdoMet d½dAdoMet
dt
~VAdoMetDCT{VSpdS
½Orn d½Orn
dt
~VOrnPt{VODC
½Put d½Put
dt
~VODC{VSpdS
½MTA d½MTA
dt
~VSpdS{VMetRcy
½Spd d½Spd
dt
~VSpdS{VTSHSyn
½TSHtot d½TSHtot
dt
~VTSHSyn{VTSHCpt
doi:10.1371/journal.pone.0053734.t002
Modelling of Polyamine Metabolism in T. brucei
PLOS ONE | www.plosone.org 12 January 2013 | Volume 8 | Issue 1 | e53734
AdoMetDC is responsible for the formation of dAdoMet, the
aminopropyl donor for the biosynthesis of Spd from Put. As is the
case for T. brucei ODC, T. brucei AdoMetDC is a stable enzyme
and has a lower turnover rate than in mammalian cells.
AdoMetDC is also a regulatory enzyme, regulated by an allosteric
mechanism with prozyme, which is an enzymatically inactive close
homologue of AdoMetDC itself. The regulation of AdoMetDC is
induced by a conformational change of the prozyme structure,
which alters the half-saturation constant of AdoMetDC activity.
Willert et al. [41] discovered that in T. brucei neither AdoMetDC
nor prozyme per se is sufficiently active to prompt normal cell
growth, and only the complex of AdoMetDC—prozyme can
maintain the physiological level of Spd. Recent work by Willert
and Phillips [16] has extended the subject to examining the
influence of AdoMetDC RNAi inhibition and prozyme knockout
on polyamine synthesis and parasite growth. A similar mechanism
of allosteric regulation was also found for T. cruzi AdoMetDC [42].
The binding of AdoMetDC with prozyme contributes to
dynamical control of metabolic fluxes in the polyamine pathway
[41]. We represent the enzyme-ligand binding between Ado-
MetDC and prozyme as a one-step conformation system, with the
plausible assumption that the ligand can interact rapidly with the
enzyme as prozyme concentration is not comparable with
AdoMetDC concentration [41], causing the reaction to occur at
a rapid equilibrating rate following linear mass action kinetics (i.e.
½Eww½S). Because prozyme levels are restricted, AdoMetDC is
present in trypanosomal cells in both ligand-occupied form and
free form. Accordingly, we express the velocity equation of the
total AdoMetDC as a superposition of two terms stemming from
the individual forms of the enzyme, as below. The representation
of regulatory capabilities in summation of distinct states has been
verified for allosteric enzymes in [43].
VAdoMetDCT~VAdoMetDCLzVAdoMetDCO ð2Þ
where
VAdoMetDCL ~k
AdoPro
cat
:½AdoMetDCT :(1{b):
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KAdoPro
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~kAdoMetDC
O
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:½AdoMetDCT :
b:
½AdoMet
KAdoMetDC
O
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O
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O
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z
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In these equations, VAdoMetDCL and VAdoMetDCO stand for the
velocity contributed by the ligand-occupied (binding with
prozyme) and free form of the enzyme, modelled as above. A
factor b represents the percent of free-form AdoMetDC
(AdoMetDCO) taking up the total enzyme concentration
(½AdoMetDCT ), thus the ligand-occupied form (AdoMetDCL)
is expressed as 1{b of the total concentration. Since the prozyme
concentration is smaller than that of AdoMetDC [16], b is
assumed to vary between 0.5 and 1 in order to reflect the
experimental observation and still allow the ligand-occupied
AdoMetDC to change within a physiologically feasible range.
Note that in the above rate equations, Put and dAdoMet have a
stimulatory and inhibitory effect respectively on the activity of free-
form AdoMetDC but not on the AdoMetDC—prozyme hetero-
dimer (the ligand-occupied form) [41]. T. brucei AdoMetDC was
thought to be insensitive to dAdoMet, which is in contrast to the
strong product inhibition exerted by its counterpart in many other
species (e.g. mammalian cells) [19]. A wide range of 1 to 1000 mM
is applied for the parameter KAdoMetDC
O
idAdoMet and the estimate from in
silico simulations can be used to qualitatively assess the contradic-
tory report for this parameter.
MAT catalyses production of AdoMet from Met in the presence
of ATP. AdoMet plays an important role in a variety of cellular
functions, such as methylation and sulphuration. Polyamines are
not inhibitory to the enzyme within the range of 10 to 5000 mM,
and positive cooperativity was only realised at higher concentra-
tions of ATP with a Hill constant (nMAT) equal to 2.0 [44]. In our
model, ATP was regarded as a constant metabolite due to the lack
of knowledge on its uptake kinetics; this is supported by the recent
work [6] that the concentration of ATP stays high and constant
under stress and non-stress conditions. The enzyme velocity is
modelled in the form below, where AdoMet exerts only a weak
inhibition on MAT, which is competitive with respect to the
substrate Met.
VMAT~V
MAT
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SpdS catalyzes Spd biosynthesis from Put in the presence of
dAdoMet, with methylthioadenosine (MTA) as a by-product.
MTA is not detectable in mammals because of its rapid
degradation rate [3,45], which gives rise to the intra-cellular
concentration of this compound being low [46]. Since no data is
available for the physiological level of MTA in T. brucei, according
to the observation in mammalian cells, MTA is assumed to hold a
small value of 20 mM in our study. The kinetic mechanism of this
enzyme is modelled below, subject to the product inhibition
[3,47]. Note that when SpdS remains wild-type, parameter lSpdS is
0, and thereby the maximum velocity of SpdS becomes time-
independent. Under perturbed conditions, the maximum velocity
of SpdS becomes time-variant and defined in accordance with the
value of parameter lSpdS .
VSpdS~V
SpdS
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:e
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:t):
½Put
K
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MetRcy catalyses the synthetic transition from MTA to Met.
MTA is recycled to Met via a series of enzymatic steps in
trypanosomes [48]. It is first converted to methylthioribose-1-
phosphate by MTA phosphorylase; the latter product is then
metabolised to keto-methylthiobutyrate, and ultimately to Met
[49]. Because of the importance of MTA recycling in cell viability,
interference with Met metabolism has been explored as a potential
drug target in mammals and Plasmodium falciparum [24,50,51]. In
mammalian cells, Met can be regenerated via enzymatic catalysis
of homocysteine [50]; however debate remains as to whether
homocysteine remethylation exists in T. brucei, given that the
enzyme catalysing this chemical transition is absent in other
related parasitic species (e.g. T. cruzi and Leishmania) [30].
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In our study, the MTA recycling path is considered as the
unique source of Met reproduction, which is assumed to occur via
a single-step reaction, as kinetics for the intermediate reactions are
not known experimentally. In T. brucei, available quantitative
descriptions for the recycling path are limited to the half-saturation
constant of MTA phosphorylase with respect to its substrate MTA.
Since the enzyme has a broad substrate specificity [52], the in vivo
maximum velocity is hard to obtain, but it is assumed to hold a
very high value [53]. Again, standard Michaelis-Menten kinetics
are applied to describe the enzyme kinetics, shown below:
VMetRcy~V
MetRcy
max
:
½MTA
K
MetRcy
mMTA
1z
½MTA
K
MetRcy
mMTA
ð5Þ
AHS catalyses the production of AdoHcy from AdoMet. The
enzyme velocity is modelled as follows, subject to strong product
inhibition by AdoHcy [54].
VAHS~V
AHS
max
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z
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AdoHcy is regarded as a constant metabolite during the in silico
simulation and a methylation index of 2:1 [28] is assumed for the
ratio of [AdoMet] to [AdoHcy] under wild-type conditions
(resulting in the constraint [AdoHcy] = 0.5:[AdoMet]) to approx-
imate the relationship between the concentrations of the
metabolites.
TSHSyn denotes the synthetic enzyme catalysing one-step
TSHtot production from Spd in the model. We employed an
irreversible Hill equation (with nSyn standing for the Hill
coefficient) to model this enzyme, which is characterised by
competitive product inhibition by TSHtot, shown as follows. This
kinetic structure allows the model to mimic the in vivo state where
TSHtot levels can be compensated by elevating its production rate
during T. brucei growth interruption (via reducing TSHtot level).
VTSHSyn~V
TSHSyn
max
:
½Spd
K
TSHSyn
mSpd
 !nSyn
1z
½TSHtot
K
TSHSyn
iTSHtot
z
½Spd
K
TSHSyn
mSpd
 !nSyn ð7Þ
TSHCpt denotes the sink reaction responsible for TSHtot
interactions with the remaining system, in order to prevent
unrestricted accumulation. Designing a suitable expression for this
abstract enzyme is challenging. A linear function of consumption
rate (an unknown parameter) multiplying the concentration of
total trypanothione was initially proposed as the minimum
consumption requirement; however the simulated behaviour of
TSHtot failed to reproduce either the steady-state or DFMO-
perturbed data. We refined the rate definition by adding to this
function an irreversible Hill equation representing enzyme-
catalysed breakdown of the metabolite. Due to the number of
existing unknowns, we approximated the consumption rate (in the
linear function) as the specific growth rate (m) to which the
consumption of total trypanothione is proportional in reality. This
combined expression later proved to be satisfactory for total
trypanothione, and simulations converged to the expected steady
state, with rapid consumption under perturbation conditions, as
shown below.
VTSHCpt~m:½TSHtot{VTSHCptmax :
½TSHtot
K
TSHCpt
mTSHtot
 !nCpt
1z
½TSHtot
K
TSHCpt
mTSHtot
 !nCpt ð8Þ
The current representations for rate equations of TSHSyn and
TSHCpt are capable of reproducing observed behaviour of total
trypanothione (TSHtot) under various experimental conditions.
These kinetic structures will inevitably be different when the
remaining metabolites in the network are integrated into this
model.
MetPt is responsible for the uptake of exogenous Met in our
model. Trypanosomes rely on a constant supply of Met, and de novo
synthesis is energetically expensive [24,25]. Standard Michaelis-
Menten kinetics are applied to model MetPt as below
VMetPt~V
MetPt
max
:
½Metexg 
KMetPt
mMetexg
1z
½Metexg 
KMetPt
mMetexg
ð9Þ
OrnPt is responsible for the uptake of exogenous Orn, which is
modelled based on the reversible Michaelis-Menten kinetics.
Exogenous Orn is considered as a constant supply into the system,
with the plasma concentration assumed to be 77 mM [13].
Parameters KOrnPteq and K
OrnPt
mP stand for the equilibrium constant
and the half-saturation constant of product Orn, respectively.
VOrnPt~(½Ornexg{ ½Orn
KOrnPteq
):
VOrnPtmax
KOrnPt
mS
1z
½Ornexg 
KOrnPt
mS
z
½Orn
KOrnPt
mP
ð10Þ
This ODE model of polyamine metabolism contains 40 kinetic
parameters, where 20 are unknown and two are solved
analytically. To ensure unit consistency of the model parameters,
we express all wild-type maximum velocities VEmax (E refers to
specific enzyme name) in units of mM per minute and hence in all
these rate equations, the derivatives of the concentrations
(d[Metabolite]/dt) are expressed in mM per minute. Some known
enzyme velocities were measured in different units, i.e. mmol per
minute per number of cells or per mg of protein, conversion of
which into the desired unit was required before carrying out model
simulations. Unit conversions are elucidated in Text S2.
Model calibration
Model calibration involves determination of model parameters
that can reproduce the system behaviour. A common procedure is
to first fit model parameters to experimental data generated by a
reference cell type (wild type) and then test the estimates on data
generated by a variation (mutant). In our study, we adopt a novel
estimation methodology - the multi-objective optimisation algo-
rithm MoPSwarm [55] - to estimate unknowns, where both the
steady-state (wild type) and the perturbed (drug treated or genetic
mutant) conditions of the pathway are handled simultaneously. It
has been demonstrated in [55] that accounting for more than one
state of the system in parameter estimation process is an
advantageous approach for obtaining reliable parameter estimates.
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In this study, the model was trained via simultaneous fitting
against both the physiological steady state and DFMO-mediated
inhibition. However, corrections had to be made before the
dataset can be used. For example, AdoMet levels in trypanosomes
during ODC inhibition by DFMO treatment, were reported as
being elevated 75 times by Fairlamb et al. [11] whilst levels of this
metabolite were almost unchanged during DFMO treatment
studied by Xiao et al. [14]. The parameter estimation process was
applied to the model to match the estimated data with an
increased AdoMet concentration. Simulation results, however,
predicted that AdoMet contents were largely unchanged and all
other metabolites were well fitted. Thus, for model calibration, we
replaced AdoMet behaviour (considerably increased) in Fairlamb’s
data set with constant dynamics (as observed by Xiao et al.);
dynamics of all other metabolites in Fairlamb’s data set remained
intact.
We used the temporal changes of the reduced trypanothione,
T(SH)2, to approximate the dynamics of total trypanothione
concentration in our model. This is because in the work by
Fairlamb et al., and in all other perturbation experiments,
measurements were made for the reduced trypanothione only.
Since the reduced trypanothione exists in much higher concen-
trations than the oxidised trypanothione in T. brucei, the reduced
trypanothione is taken to represent the trends in total trypa-
nothione changes over time.
The polyamine model under steady-state (wild type) and
DFMO-treated (perturbed) conditions differ in the mathematical
representation of VODC , as the maximum velocity of ODC (V
ODC
max )
is a time-invariant parameter in the former case and a time-
dependent exponential decay in the latter. Uptake kinetics of
DFMO have not been measured. Despite the absence of a
quantitative description, the DFMO-induced inhibition is well
understood in a qualitative sense, where ODC activity decreased
by more than 99% within 12-hour of treatment with DFMO [11].
ODC activity in response to DFMO is therefore modelled with an
exponential decay function by multiplying the original rate
equation of ODC (Equation 1 in the Model Descriptions section
of Materials and Methods) with term e{lODC
:t to reflect the time-
dependent response of enzyme activity to the drug inhibition,
whilst remaining terms in the equation are unchanged, shown
below. Parameter lODC takes a value of 0.007 in this instance,
solved by simple curve fitting using the qualitative description.
VODC~ ½Orn{ ½Put
KODCeq
 !
:
e({lODC
:t):VODCmax
:e
({lSpdS
:t)
KODC
mOrn
1z
½Orn
KODC
mOrn
z
½Put
KODC
mPut
:(1z
½Put
KODC
iP
)
0
BBBB@
1
CCCCA ð11Þ
Note that in this equation parameters lODC and lSpdS correspond
to different inhibitory scenarios, namely ODC inhibition (resulting
from DFMO drug uptake or ODC enzyme perturbation) and
SpdS inhibition, respectively. It is only when ODC and SpdS
inhibition are applied in tandem that both parameters are given
non-zero values. In other words, except in SpdS-inhibited
conditions, lSpdS equals zero under both steady-state and
DFMO-induced conditions as well as all other perturbed
conditions.
In our model, initial concentrations are treated as unknown
parameters to be estimated together with the unknown kinetic
parameters. Our choices of the initial metabolite concentrations
are restricted to+20% of the measured physiological levels when
fitting the polyamine model to the given steady state. This helps
the convergence of the optimisation algorithm from random
positions in the search space. The solutions returned from the
estimation procedure are ranked according to their importance in
satisfying both pathway states using the root mean square of the
two objectives with respect to an individual state, and the best
trade-off solution with the highest rank is selected for investigation.
Details on the optimisation algorithm, the objective functions and
the ranking method used for parameter estimation and selection
are given in Text S3.
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